Background. Our objective was to determine the impact of combination antiretroviral therapy (cART) and the degree of immunosuppression on biologic false-positive (BFP) rapid plasma reagin (RPR) tests among persons infected with human immunodeficiency virus (HIV).
The diagnosis and management of most stages of syphilis require reactivity of both nontreponemal and treponemal antibody tests. Nontreponemal tests use cardiolipin-lecithin-cholesterol antigens to detect crossreacting lipid antibodies. The 2 most commonly used nontreponemal tests are the rapid plasma reagin (RPR) test and the Venereal Disease Research Laboratory (VDRL) test. The RPR test, an integral part of screening for syphilis, requires confirmation with treponemalspecific antibodies. Historically, biologic false-positive (BFP) reactions (reactive RPR or VDRL tests with nonreactive treponemal antibody tests) have been associated with acute febrile illnesses, pregnancy, collagen vascular diseases, immunization, viral hepatitis, older age, injection drug use (IDU), hepatitis C virus (HCV) infection, and human immunodeficiency virus (HIV) infection [1] [2] [3] [4] [5] .
In contrast to the general population where the prevalence of BFP has been reported to be <5% [4] , the prevalence of BFP ranges from 4% to 15% among HIVinfected persons [5] [6] [7] . Persons with HIV have abnormalities in B-cell activation and immunoregulation that are hypothesized to play a role in the occurrence of BFP reactions in this population [8] . Indeed, some antibodies directed against the HIV type 1 (HIV-1) envelope have been found to react with the phospholipid cardiolipin [9, 10] . With the advent of combination antiretroviral therapy (cART), certain parameters of HIV-1-induced B-cell dysfunction are reversed. However, it is currently not known if the immune recovery with cART decreases the incidence of BFP reactions.
In this study, we describe the impact of cART use and the resulting immunologic response on the prevalence of BFP reactions among persons infected with HIV.
METHODS
This is a retrospective study nested in the Johns Hopkins HIV Clinical Cohort whose characteristics have been described elsewhere [11] . Data have been collected on HIV-infected persons enrolled in this cohort since 1990. After informed consent is obtained for patients participating in the cohort, a baseline evaluation of medical and social histories, physical examination, and laboratory studies are recorded and prospectively updated from the clinic-based medical record every 6 months with any new medical diagnoses, hospitalizations and procedures, filled prescriptions, and laboratory and radiographic results. Use of this database for the analysis of patient outcomes is approved by the institutional review board of the Johns Hopkins University School of Medicine. Participants in the cohort with positive and negative screening tests for syphilis based on a reactive and nonreactive RPR from 1990 through 2011 were eligible for inclusion into this study. All patients had confirmatory testing with fluorescent treponemal antibody absorption (FTA-ABS) test except patients with nonreactive RPR tests. A BFP test was defined as a reactive RPR followed by a nonreactive FTA-ABS test, and syphilis infection was defined as a reactive RPR test followed by a reactive FTA-ABS. A negative syphilis test was defined by a nonreactive RPR and no clinical findings suggestive of syphilis.
Sociodemographic information (age, sex, and ethnicity), RPR titer, CD4 cell counts (cells/mL), plasma HIV RNA measurements (copies/mL), hepatitis B virus (HBV) status (defined by the presence of hepatitis B surface antigen [HBsAg] ) and HCV status (defined by the presence of hepatitis C antibody), IDU (which was the HIV transmission risk group and represents a history of prior IDU or current IDU), and data on antiretroviral therapy use were also extracted from the database. Of note, HIV RNA measurements were not available until 1996 and HCV testing was not available until 1995. Age was examined as a continuous variable and as a dichotomous variable in years (less than median age or greater than or equal to median age). Sex, ethnicity, IDU, HBV status, HCV status, and cART use were evaluated as dichotomous variables.
RPR titer was evaluated as a continuous variable and as a logarithm base 2-transformed continuous variable. CD4 was evaluated as a continuous variable and as a categorical variable (CD4 cell count ≤200 cells/mL or >200 cells/mL). HIV RNA level was evaluated as a logarithm base 10-transformed continuous variable and further divided into 3 RNA strata (≤200 copies/mL HIV RNA, >200 copies/mL but <100 000 copies/ mL, and ≥100 000 copies /mL). Antiretroviral therapy was classified as use of at least 1 antiretroviral agent and "unknown" if data were not available on antiretroviral use. cART was defined as concomitant use of ≥3 antiretroviral drugs from at least 2 different classes or the use of 3 nucleoside reverse transcriptase inhibitors for a duration of at least 6 months.
We conducted 2 analyses: the first was a cross-sectional analysis assessing for factors associated with a BFP test result at the first clinic visit with a BFP result. We compared persons with BFP results with 2 control groups. The first control group included patients with active syphilis (reactive RPR and FTA-ABS) diagnosed over the same time period . The second control group consisted of patients without current syphilis (based on a nonreactive RPR) who were matched on age, sex, and time period (same year) surrounding the BFP RPR test date. The second analysis was a longitudinal analysis restricted to persons with BFP tests. We assessed for patterns of BFP test variation over time among persons with at least 2 visits with a documented RPR test result, to determine factors associated with persistent BFP tests. This group was subdivided into "persisters" and "nonpersisters." Persisters were defined as having at least 2 documented visits with consistent BFP at all visits, and nonpersisters were defined by the presence of at least 1 occurrence of nonreactive RPR across follow-up visits.
Univariable and multivariable logistic regression was used to assess the association between the covariates and the first occurrence of a BFP RPR test. CD4 and HIV RNA level were included as continuous and categorical variables in the univariable model. In the multivariable model, they were included as categorical variables to examine the effect of immunosuppression and virologic control. We used χ 2 test to compare independent proportions, the K equality of medians test to compare independent median values, and the independent t test to compare mean values. We used generalized estimating equations to assess the association between the covariates and persistent BFPs to account for repeated measures at followup visits. All analyses were performed using Stata/SE version 12.0 (StataCorp, College Station, Texas). For the first analysis, we defined statistical significance as P < .03 for a 2-tailed test using a modified Bonferroni adjustment for multiple comparisons. For the second analysis looking at BFP persistence, we defined statistical significance as P < .05 based on a 2-group comparison.
RESULTS
Overall, 711 patients were included in the initial cross-sectional analysis. Of those, 96 (13.5%) had BFP tests, 342 (48.1%) had active syphilis infection, and 273 had negative serum RPR (18 had previously treated syphilis). The median age in the population was 41 years, and 693 patients (97.5%) were <60 years of age (Table 1) . Among the 711 patients, 188 (26.4%) had evidence of HBV, 402 (56.5%) had HCV, 324 (45.6%) reported ever IDU, and 343 (48.2%) were on cART. IDU and HCV were more prevalent in the BFP group compared to controls. cART use was more prevalent in both control groups compared to BFP patients (Table 1) . Patients with BFP tests had lower median RPR titers compared to patients with syphilis. The median CD4 did not differ between cART and non-cART users, but the median HIV RNA was greater in non-cART users (4.35 log copies/mL) compared to cART users (2.26 log copies/mL) (P < .01).
Comparing patients with BFP test results to patients with syphilis by multivariable analysis, IDU was the strongest predictor of increased odds of BFP tests followed by HBV (Table 2) . cART use was the strongest predictor of decreased odds of BFP tests followed by increasing RPR titer per log RPR increase. CD4 and HIV RNA were not associated with BFP tests. Comparing patients with BFP test results to patients without syphilis by multivariable analysis, IDU lost its statistical significance but cART use remained protective against BFP tests (Table 2) .
For the longitudinal analysis assessing for predictors of persistence of BFP tests, of the 96 patients with BFP RPRs, 18 (18.7%) had a single visit with BFP RPR and were excluded from the assessment. Of the 78 (81.3%) patients with at least 2 visits with documented RPR test results, 4 (5.1%) had at least 1 occurrence of a true positive RPR across visits and 3 (3.8%) switched from true positive to minimally reactive RPRs. These 7 patients were also excluded from the assessment of BFP persistence. Of the remaining 71 patients, 22 (28.2%) had persistent BFP RPRs across all visits and were classified as persisters whereas 49 (62.8%) were classified as nonpersisters based on the presence of at least 1 occurrence of nonreactive RPR across follow-up visits. At baseline, both groups only differed by mean number of RPR tests and cART use ( Table 3 ). The nonpersisters averaged 5.9 tests compared to 3.7 tests among the persisters (P < .01). cART use was more prevalent among nonpersisters compared to persisters (34.7% compared to 9.1%; P = .02). Their CD4 counts were comparable but HIV RNA levels were higher among the nonpersisters (P = .03). In univariable analysis, cART use predicted a decreased persistence of BFP tests at baseline and subsequent visits (unadjusted odds ratio, 0.07; 95% CI, .01-.33; Table 4 ). No other variables were associated with BFP persistence. Given the small sample size, we did not construct a multivariable model.
DISCUSSION
Our findings indicate that cART use decreases the odds of a BFP test result. HIV infection has been hypothesized to be associated with BFP reactions as a result of B-cell dysregulation leading to hypergammaglobulinemia, polyclonal B-cell activation, and the production of antiphospholipid antibodies [8] [9] [10] . cART reverses some of these changes [12] [13] [14] . Consequently, we hypothesized that the impact of cART on B-cell function may result in a decline in the occurrence of BFP tests. Our results support this hypothesis. We published previously that cART resulted in enhanced serological response rates among HIV-infected persons with syphilis [15] . Although this may reflect cART-induced enhanced immunological control of syphilis, resulting in a drop in the nontreponemal titers, our current findings suggest a possible alternate hypothesis: cARTinduced reversal of B-cell dysfunction, resulting in a drop in nontreponemal titers, independent of underlying syphilis disease activity. In this study, we did not directly assess B-cell function, so we cannot rule out the role of other unrelated cART mechanisms. Our adjusted analysis did not show an association between CD4 and BFPs. The lack of an association between BFP and CD4 was also noted in a prospective investigation of BFP syphilis tests in the Women's AIDS cohort study [16] . Previous studies on BFP tests in HIV-infected patients have not explored the effect of active HIV RNA replication [7, [16] [17] [18] . We observed a trend toward increased odds of BFP when comparing individuals with BFP and HIV RNA >100 000 copies/mL to similar patients with syphilis. Whether the association between high HIV RNA values and BFP simply reflects underlying immune dysfunction or some other phenomenon is not known.
IDU has been previously shown to be associated with BFP tests [5, [16] [17] [18] [19] [20] [21] [22] [23] . Studies have noted a BFP prevalence ranging from 5.8% [16] to 95% [22] among injection drug users. The prevalence of BFP tests in our study is higher than the 4% prevalence among HIV-infected patients attending sexually transmitted disease (STD) clinics in Baltimore reported by Rompalo et al [7] . This difference may be due to the lower IDU prevalence in the STD clinic population [7] . A potentially important aspect of IDU is duration of use, amount of use, and drug used. A study of ongoing substance users noted a 59% prevalence of BFP tests [21] compared to 33% prevalence among former Abbreviations: cART, combination antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; IDU, injection drug use; OR, odds ratio; RPR, rapid plasma reagin.
*P values represent statistical differences between patients with biologic false-positive tests and control groups (patients with true syphilis and syphilis-negative patients).
addicts who had not taken drugs for a year or more [23] . This suggests that current vs remote drug use may influence the effect of IDU on BFP. We did not account for other salient aspects of IDU that may impact BFP. HCV was associated with BFP tests only in univariable analyses. After adjusting for IDU, HCV was no longer associated with BFP tests, a finding similar to a prior study by Thomas et al [5] . However, other studies have noted an association between HCV and BFP tests [19, 24] . Augenbraun et al found this association even after adjusting for IDU [19] . The inconsistent association between HBV and BFP in our study is more difficult to explain. HBV increased the odds of BFP when the BFP group was compared to persons with syphilis. This association was not evident when comparing the BFP group to persons without syphilis. A previous study among injection drug users noted an association between BFP tests and the presence of antibodies to hepatitis B core antigen but no association with HCV [18] . Even though our study defined HBV status differently based on the presence of HBsAg, if HBV were a cause of BFP, one would expect a more consistent association. It is important to note that based on the available data, we could not determine which individuals had active HBV infection. Thus, differences in HBV disease activity between persons with syphilis and those without syphilis may explain our findings. Another possibility is that HBV may be a proxy for some other unmeasured variable.
Persons with BFP tests had lower RPR titers compared to those with syphilis infection. This finding is consistent with previously reported data [4, 7, 20] . Unlike other studies [4, 7, 12] , we found a trend toward increased odds of BFP tests in patients aged <41 years when compared to persons with syphilis. Geusau et al noted a higher proportion of BFPs in patients >60 years of age than those <60 years in a population in Austria [4] . In contrast, Rompalo et al [7] and Augenbraun et al [16] did *P values represent statistical differences between patients with persistent BFP tests (n = 22) and nonpersistent tests (n = 49) using generalized estimating equation.
not observe any age differences between HIV-infected patients with BFP tests compared to true syphilis infection. Our study had very few patients older than age 60. In addition, patients <41 years of age were more likely to have detectable HIV RNA, which may be a reflection of immune dysfunction and, consequently, increased probability of BFP. We could not explore the relationship of age to BFP in the comparison to patients without syphilis because the 2 groups were matched on age. Our study has several limitations. The high prevalence of concurrent risk factors for BFPs such as viral hepatitis and IDU makes it difficult to ascertain the relative contribution of a single factor to BFP occurrence. In addition, the small sample size of patients with BFP results may have limited our ability to detect other meaningful differences, particularly in our analysis of persistence. Syphilis testing was not batched, which may have introduced some variability in the results. In addition, our study did not assess for the effect of active vs remote IDU on BFP, and we could not assess HBV disease activity. We had few women in our study; this mainly reflects the epidemiology of syphilis in the United States [25] . In addition, because of the inability to test for HCV before 1995, earlier enrollees in our cohort may have been inadequately classified as HCV negative. However, this is unlikely to have impacted our results as these earlier enrollees would have been retested in later years.
We found that cART is associated with decreased odds of BFP in persons with HIV, perhaps as a result of improved B-cell function. Indirectly, our findings suggest that nontreponemal titer fluctuations in persons with HIV may reflect the influence of factors unrelated to syphilis disease activity. The reliance on serological tests that are indirect measures of syphilis disease activity will continue to challenge clinicians and researchers who are making decisions based on these tests.
Notes

